Fidelity Select Biotechnology Portfolio Income Tax

The latest income tax for FBIOX is $-1.4M as of September 2023. That compares with $-48M in the prior-year period — up 97.2% year over year. Investors often review this figure alongside Fidelity Select Biotechnology Portfolio's historical trend and sector peers before judging valuation or financial health.

Over the past year, FBIOX's income tax moved from $-48M to $-1.4M — a 97.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fidelity Select Biotechnology Portfolio's operating scale or balance-sheet position.

A income tax figure of $-1.4M for FBIOX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting FBIOX's income tax ($-1.4M), review year-over-year change from $-48M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.